Award recordCONTRACT

GRIFOLS THERAPEUTICS LLC

PIID VA26016F4263· VHA· 260-NETWORK CONTRACT OFFICE 20 (36C260)· 6810 · CHEMICALS· FY2016· $197,165 net obligations· UEI UFQ3A7GKJ5C7· NC

Description

DRUG ORDER MOD TO REMOVE EXCESS FUNDING AND CLOSEOUT

Base award description: DRUG ORDER

First action · last action
2015-10-01 · 2016-11-29
Transactions
3
First transaction's obligation
$221,900
Base + all options value (sum of deltas)
$197,165
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797D30042
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 3 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$221,900$0Base award · 2015-10-01 · this action $221,900 · running total $221,900Modification P00001 · 2016-09-02 · this action $0 · running total $221,900Modification P00002 · 2016-11-29 · this action -$24,735 · running total $197,165
  • Base2015-10-01+$221,900= $221,900
  • Mod P000012016-09-02+$0= $221,900
  • Mod P000022016-11-29-$24,735= $197,165
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2015-10-01+$221,900$221,900DRUG ORDER
Mod P00001· FUNDING ONLY ACTION2016-09-02+$0$221,900DRUG ORDER
Mod P00002· CLOSE OUT2016-11-29−$24,735$197,165DRUG ORDER MOD TO REMOVE EXCESS FUNDING AND CLOSEOUT

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI UFQ3A7GKJ5C7)

AwardOffice · PSC / listingNet obligationsFY
36C26022F0140260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$100,282FY2022
36C26022F0004260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$454,461FY2022
36C26021F0264260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$130,406FY2021
36C26021F0117260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$75,000FY2021
36C26021F0014260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$220,000FY2021
36C26021F0021260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$355,273FY2021

Other recipients under 6810 from 260-NETWORK CONTRACT OFFICE 20 (36C260) (most recent first)

AwardRecipientOfficeNet obligationsFY
36C26018P3900LIFE CHEMICALS INC260-NETWORK CONTRACT OFFICE 20 (36C260)$80,976FY2018
VA26018P2530BSE PERFORMANCE, LLC260-NETWORK CONTRACT OFFICE 20 (36C260)$24,960FY2018
VA26017F0129UNITED THERAPEUTICS CORP260-NETWORK CONTRACT OFFICE 20 (36C260)$91,147FY2017
VA26017J3080ARIAD PHARMACEUTICALS, INC.260-NETWORK CONTRACT OFFICE 20 (36C260)$79,221FY2017
VA26016F1444LUNDBECK LLC260-NETWORK CONTRACT OFFICE 20 (36C260)$6,829FY2016

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA26016F4263_3600_V797D30042_3600 · retrieved 2026-09-26.